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Abstract
Background: Peptidyl-prolyl isomerase, NIMA-interacting 1 (PIN1) plays a significant role in the
brain and is implicated in numerous cellular processes related to Alzheimer's disease (AD) and
other neurodegenerative conditions. There are confounding results concerning PIN1 activity in AD
brains. Also PIN1 genetic variation was inconsistently associated with AD risk.
Methods: We performed analysis of coding and promoter regions of PIN1 in early- and late-onset
AD and frontotemporal dementia (FTD) patients in comparison with healthy controls.
Results: Analysis of eighteen PIN1 common polymorphisms and their haplotypes in EOAD, LOAD
and FTD individuals in comparison with the control group did not reveal their contribution to
disease risk.
In six unrelated familial AD patients four novel PIN1 sequence variants were detected. c.58+64C>T
substitution that was identified in three patients, was located in an alternative exon. In silico analysis
suggested that this variant highly increases a potential affinity for a splicing factor and introduces
two intronic splicing enhancers. In the peripheral leukocytes of one living patient carrying the
variant, a 2.82 fold decrease in PIN1 expression was observed.
Conclusion: Our data does not support the role of PIN1 common polymorphisms as AD risk
factor. However, we suggest that the identified rare sequence variants could be directly connected
with AD pathology, influencing PIN1 splicing and/or expression.
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Background
PIN1 is a ubiquitously expressed protein, belonging to the
evolutionarily conserved peptidyl-prolyl isomerase (PPI-
ase) family. PIN1 isomerizes p(Ser/Thr)-Pro motifs in the
target proteins, which leads to the alteration of their struc-
ture, function, intracellular localization and/or stability
[1]. Previous studies have demonstrated that PIN1 plays a
crucial role in multiple cellular processes and, likewise, it
has been implicated in pathogenesis of several diseases,
including cancer, inflammation to neurodegenerative dis-
eases [2-8].
The gene encoding PIN1 maps to chromosome 19p13.2,
a region associated with late-onset Alzheimer's disease
(LOAD) [9]. Moreover, PIN1  is the only known gene
whose knockout in mice can cause both Tau and Aβ-
related pathologies in an age-dependent manner [4,10]. It
was shown that PIN1-catalysed conformation change of
pT668 could prevent amyloidogenic processing of APP
[10]. Additionally, in a similar manner PIN1 may indi-
rectly reverse the hyperphosphorylation of Tau, restoring
its ability to bind microtubules, as well as inhibit GSK3β
phosphorylation [5,11]. As overexpression of PIN1 in
vitro induced a reduction in amyloidogenic processing of
APP, it has been proposed that functional PIN1 could pre-
vent or slow down AD onset [10]. On the other hand,
PIN1 dysfunction or down-regulation e.g. under the oxi-
dative stress, would favor cis form of pT668 APP and toxic
Aβ production, leading finally to neurodegeneration
[5,12,13]. However, there are confounding results consid-
ering the activity and the role of PIN1 in AD [14]. PIN1
protein was depleted in hippocampi of AD patients
[2,15]. However, others showed that in the cortex of the
frontal lobes of MCI and AD patients PIN1 levels and
activity were increased compared to healthy controls [16].
Recently, PIN1 expression has been shown to increase
during neuronal differentiation, which led to suggestion
that PIN1 dysfunction or downregulation could favor cell
cycle re-entry [17-19]. This could result in aneuploidy
observed in AD patients brains [20]. Indeed, several lines
of evidence indicate that disturbed maintenance and seg-
regation of chromosomes, DNA damage and impaired
repair could contribute to AD [21-23].
PIN1 downregulation or dysfunction could result not
only from oxidative stress, but also could be connected
with genetic variability [10,12,15,17,24]. Segat et al. dem-
onstrated that the carriers of PIN1 -842C allele and/or -
842C/-667C haplotype have an increased risk of AD,
lower age of onset, and reduced PIN1 levels in peripheral
mononuclear cells [12]. Moreover, individuals with
amnestic MCI recruited from the same population
showed a similar genotype distribution of -842 SNP as AD
patients in Segat et al. (2007) study [12,25]. However,
other studies on the role of PIN1 genetic variants in AD
did not repeat the initial findings [26-28].
To our knowledge, a thorough analysis of haplotypes that
are formed by a set of PIN1 SNPs has not been described
yet. Moreover, there were no studies on the involvement
of PIN1 variants in early onset AD (EOAD), familial AD,
and FTD, despite the fact that decreased PIN1 expression
and depletion of neuronal nuclear PIN1 has been sug-
gested to be a common feature in AD and FTD [7]. Given
supporting evidence for PIN1 role in the brain, and yet
unresolved influence of PIN1 sequence variation in AD
and FTD, we decided to perform an exhaustive analysis of
PIN1 in a group of Polish AD and FTD patients.
Methods
111 late onset (mean age of onset ± SD: 73.2 ± 5.0 years,
range 66-88; 69.4% females) and 49 early onset AD
patients (mean age of onset ± SD: 52.6 ± 9.8 years; 57.1%
females), and 57 frontotemporal dementia (FTD) patients
(mean age of onset: 59.3 ± 12.3 years; 43.9% females)
were recruited for the study. Twenty-six patients in the
EOAD group have a family history of AD recorded, and 70
patients in the LOAD group claim a family history of
dementia. The control group consisted of 104 healthy,
non-demented individuals (mean age ± SD: 75.1 ± 5.2
years, range: 68-90; 71.15% females). AD diagnosis ful-
filled the criteria of National Institute of Neurological and
Communicative Disorders and Stroke - Alzheimer's Dis-
ease and Related Disorders Association (NINCDS-
ADRDA) for probable AD, whereas FTD was diagnosed
according to Lund and Manchester Groups (1994) and
Neary (1998) criteria [29,30]. The control subjects had
normal mental status test scores and no clinical evidence
of cognitive deficits in neurological examination.
All participants or their relatives provided written,
informed consent and the study was approved by the Eth-
ics Committee of the MSWiA Hospital in Warsaw in
accordance with the principles of the Helsinki Declara-
tion.
PIN1 promoter (1545 kb upstream the ATG translation
initiation codon; NCBI GenBank AF501321) and coding
regions (4 exons with flanking intronic regions of about
100 nt; NCBI GenBank NM_006221, NC_000019.8) were
amplified (primers are listed in Additional file 1). Ana-
lyzed fragments covered 18 annotated DNA variations
(rs7247933, rs4804459, rs2233678, rs35794537,
rs2233679, rs2233680, rs7250788, rs35973416,
rs28589723, rs2233681, rs2233682, rs2233683,
rs2010457, rs11540415, rs34412035, rs11540414,
rs3178950, rs35575918).BMC Medical Genetics 2009, 10:115 http://www.biomedcentral.com/1471-2350/10/115
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APOE genotypes were determined as described previously
[31]. Patients and controls were stratified into two sub-
groups, according to APOE status: those carrying at least
one  APOE4  allele (APOE4+) and APOE4  non-carriers
(APOE4-).
First, sequencing of PIN1 in DNA samples from EOAD
and FTD patients was performed. Four identified variants
in EOAD patients were screened in the control group and
LOAD patients using denaturing high performance liquid
chromatography (dHPLC). DHPLC analysis was per-
formed as described previously (for DHPLC temperature
for the analysis of PIN1 gene fragments see Additional file
2) [32,33]. Both groups were also screened for SNPs het-
erozygous in the Polish population (rs4804459,
rs2233678, rs2233679, rs2233682, rs2233683,
rs2010457).
The identified promoter DNA substitution was examined
for introducing potential differences in transcription fac-
tor binding sites using MatInspector (Geneomatix soft-
ware, Germany, [34]) and Mapper http://bio.chip.org/
mapper. The possible effect of identified DNA variants on
splicing was investigated using ESEfinder (release 3.0)
[35,36] and Automated Splice Site Analyses [37,38]. ESE-
finder identifies putative exon splicing enhancers respon-
sive to the human serine/arginine-rich (SR) proteins,
whereas Automated Splice Site Analyses evaluates changes
in splice site strength based on information theory based
models. Analysis of intronic sequences containing muta-
tions were done also with application of RegRNA: A Reg-
ulatory RNA Motifs and Elements Finder http://
regrna.mbc.nctu.edu.tw/index.html. ConSeq http://con
seq.bioinfo.tau.ac.il/ program was used to evaluate the
degree of conservation of mutated residue in the protein
coding sequence.
Total RNA was isolated from leukocytes of the patient
with c.58+64C>T variant and four healthy individuals,
using standard TRI Reagent® method, according to manu-
facturer's procedure (Ambion). The SuperScript First-
Strand Synthesis System for RT-PCR (Invitrogen) was used
to synthesize first-strand cDNA, using oligo-dT primers
and equal amount of RNA from the samples. Then all
samples were adjusted to 20 ng/μl cDNA. qPCR was per-
formed in triplicates in a 25 μl reaction mix with 3 μl of
diluted cDNA template, using standard SYBR Green pro-
tocol on ABI 7500 Sequence Detection System (Applied
Biosystems). The thermal cycling conditions comprised
an initial denaturation step at 95°C, then 40 cycles of
95°C for 15 s and 60°C for 1 min. The temperature range
used for the melting curve generation was from 60°C to
95°C. The dissociation plots indicated a single peak in all
reactions.
The primer set for PIN1 was designed to span intron 3 in
order to distinguish amplified cDNA from genomic DNA.
No primer dimers were observed. The level of PIN1 mRNA
was normalized to that of succinate dehydrogenase com-
plex subunit A (SDHA). The relative quantification
method was applied to analyze real-time PCR results.
Similar efficiencies of target and reference genes allowed
us to use the comparative Ct method (2-deltadeltaCt) to cal-
culate relative expression of PIN1 in our patient in com-
parison with four healthy individuals.
Comparisons of allele and genotype frequencies between
the affected and the control group were carried out using
the chi-square or Fisher exact (2-tailed) tests. The Hardy-
Weinberg equilibrium was tested using a chi-square good-
ness-of-fit test. Kruskal-Wallis test was used to compare
age at onset of LOAD symptoms between genotype
groups. Statistical difference was accepted at p < 0.05.
Haplotype assignment and linkage disequilibrium (LD)
between each pair-wise combination of SNPs hetero-
zygous in the studied groups as expressed by D' was calcu-
lated using the Haploview 4.0 (http://
www.broad.mit.edu/mpg/haploview/, [39]). Haplotypes
were inferred using EM algorithm, which was imple-
mented in Haploview [40].
Results
Genotyping promoter region and 4 exons with adjacent
flanking intron sequences of the PIN1 gene revealed six
heterozygous polymorphisms (rs4804459, rs2233678,
rs2233679, rs2233682, rs2233683, rs2010457) that were
included in the further analysis. SNPs rs4804459,
rs2233678, rs2233679 and rs2010457 were in linkage
disequilibrium in LOAD, EOAD, FTD and control groups
(Figure 1). SNPs rs2233682 and rs2233683 had low
minor allele frequency.
Genotype and allele frequencies of investigated polymor-
phisms were similar in LOAD, EOAD, FTD patients in
comparison with the controls. Distribution of polymor-
phisms heterozygous in the studied groups is presented in
Table 1. All observed genotype frequencies in the affected
and the control group were in the Hardy-Weinberg equi-
librium (p > 0.05). The statistical power for comparison of
the LOAD (n = 111) and the control (n = 104) groups was
sufficient to detect with 80% probability true differences
of the allele and haplotype frequencies in the range from
5% (for the most rare alleles) to 12% (for the most com-
mon alleles). The respective detectable differences were
6% to 17% for both EOAD (n = 49) and FTD (n = 57)
groups when compared to the controls.
There were significantly more APOE4 carriers among the
LOAD patients (63.06%) in comparison to the controlBMC Medical Genetics 2009, 10:115 http://www.biomedcentral.com/1471-2350/10/115
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group (21.15%) (χ2 = 38.52, df = 1, p < 0.00001). Stratifi-
cation of the LOAD patients and the control group accord-
ing to the APOE4 status had no influence on their allele or
genotype distribution - there were no significant differ-
ences between the groups (p > 0.1, data not shown). In
addition, none of the studied polymorphisms affected the
age at onset of LOAD symptoms (p > 0.1, data not
shown).
Polymorphisms heterozygous in the studied groups deter-
mined 3 major haplotypes (Table 2). Among them, the
most frequent one, CGTGCA was present in >64% chro-
mosomes. GGCGCG and CCCGCG had a frequency
>17% and >9%, respectively. Other identified haplotypes
had minor frequencies (<3%). None of the haplotypes
was associated with disease status (Table 2).
The number of haplotypes within the 14 kb block was
greater than the number of SNPs plus one. However, the
excess of haplotypes (11 vs 6+1, respectively, Table 2) was
still small, which could suggest relatively few recombina-
tion events in the past.
Four novel PIN1 variants were identified in six unrelated
patients with familial AD (summarized in Table 3). All of
identified variants were nucleotide substitutions absent in
the control group. We detected one promoter mutation
(g.9805834T>C, GenBank AF501321), localized 1187
bases upstream the translation start codon. In exon 1 a
silent substitution was found (c.24C>T, GenBank
NM_006221 and NC_000019.8), changing the third base
of codon 8. Two other variants were localized in introns,
c.58+64C>T in intron 1 and c.382+105C>T in intron 3.
No sequence alterations were detected in the patients with
FTD. As PIN1 was postulated to play an important role in
oncogenesis, any recognized tumor or cancer in life his-
tory of analyzed patients with PIN1 variants was indicated
in Table 3.
Unfortunately, out of the six mutation carriers, only one
was available for further investigation. The other five indi-
viduals died before the conduction of the study. As Fang-
hänel et al. (2006) suggested, Pin1 activity is mainly
controlled by its expression level. Therefore, in order to
asses  PIN1  expression in the carrier of variant
c.58+64C>T, we performed quantitative PCR. Relative
quantification, using endogenous control gene, SDHA,
and four healthy individuals for data normalization,
revealed a 2.82 decreased PIN1 mRNA level in the patient
(Additional file 3).
Discussion
Several lines of evidence indicate the importance of PIN1
in the nervous system. PIN1 is expressed in different brain
regions at least three-fold higher than in other tissues [41]
and has been postulated to be involved in neuronal differ-
entiation and in maintaining normal neuronal functions
and their postmitotic state [3,4]. Moreover, PIN1 was
demonstrated to have a pivotal role in protecting against
age-related neurodegeneration [4]. In Alzheimer's disease
PIN1 depletion was related to exacerbated tau hyperphos-
phorylation, generation of NFT and neurotoxic Aβ and
subsequent amyloid plaque formation. Additionally,
PIN1 depletion was suggested to contribute to neuronal
apoptosis [42].
To test the hypothesis that PIN1 dysfunction in AD and/
or FTD could be connected with genetic variability, we
analyzed the promoter and coding regions of PIN1.
Our data does not support the role of 18 common PIN1
polymorphisms as AD or FTD risk factors. Neither indi-
vidual alleles, nor haplotypes were associated with EOAD,
LOAD or FTD risk. Our findings conflicted with Segat et
al. (2007) reports of -842C SNP and -842C/-667C haplo-
Pairwise linkage disequilibrium between the six genotyped  SNPs in a 14 kb region of PIN1 (Haploview 4.1) for combined  group (n = 321) of all patients (LOAD, EOAD and FTD) and  controls Figure 1
Pairwise linkage disequilibrium between the six gen-
otyped SNPs in a 14 kb region of PIN1 (Haploview 
4.1) for combined group (n = 321) of all patients 
(LOAD, EOAD and FTD) and controls. Numbers inside 
the squares represent the D' value expressed as a percent. 
Squares without numbers represent D' values of 1.0, indica-
tive of complete linkage disequilibrium. Darker-shaded 
squares represent pairs with LOD score for linkage disequi-
librium of = 2, light grey squares represent D' = 1 but LOD 
<2, and white squares represent LOD <2 and D' <1.0.BMC Medical Genetics 2009, 10:115 http://www.biomedcentral.com/1471-2350/10/115
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Table 1: Frequencies of six heterozygous in the Polish population PIN1 polymorphisms
SNP Genotype n (%) Allele n (%)
rs4804459 GG GC CC p-value G C p-value
Controls 3 (2.88) 33 (31.73) 68 (65.38) controls vs LOAD
patients: p = 0.925
39 (18.75) 169 (81.25) controls vs LOAD
patients: p = 0.841
LOAD patients 2 (1.80) 36 (32.43) 73 (65.77) 40 (18.02) 182 (81.98)
EOAD patients 3 (6.12) 13 (26.53) 33 (67.35) controls vs EOAD patients p 
= 0.504
19 (19.4) 79 (80.6) controls vs EOAD
patients: p = 0.887
FTD patients 1 (1.75) 22 (38.60) 34 (59.65) controls vs FTD
patients: p = 0.462
24 (21.05) 90 (78.95) controls vs FTD
patients: p = 0.617
Differences between 4 
groups: p = 0.668
Differences between 4 
groups: p = 0.925
rs2233678 GG GC CC p-value G C p-value
Controls 82 (78.85) 21 (20.19) 1 (0.96) controls vs LOAD
patients: p = 0.715
185 (88.94) 23 (11.06) controls vs LOAD
patients: p = 0.439
LOAD patients 83 (74.77) 26 (23.42) 2 (1.80) 192 (86.48) 30 (13.51)
EOAD patients 34 (69.39) 15 (30.61) 0 (0.00) controls vs EOAD
patients: p = 0.323
83 (84.7%) 15 (15.3) controls vs EOAD
patients: p = 0.263
FTD patients 46 (80.70) 10 (17.54) 1 (1.75) controls vs FTD
patients: p = 0.924
102 (89.47) 12 (10.53) controls vs FTD
patients: p = 0.885
Differences between 4 
groups: p = 0.673
Differences between 4 
groups: p = 0.632
rs2233679 CC CT TT p-value C T p-value
Controls 9 (8.65) 45 (43.27) 50 (48.08) controls vs LOAD
patients: p = 0.928
63 (30.3) 145 (69.7) controls vs LOAD
patients: p = 0.708
LOAD patients 11 (9.91) 49 (44.14) 51 (45.95) 71 (31.98) 151 (68.02)
EOAD patients 5 (10.20) 25 (51.02) 19 (38.78) controls vs EOAD
patients: p = 0.560
35 (35.7) 63 (64.3) controls vs EOAD
patients: p = 0.343
FTD patients 3 (5.26) 30 (52.63) 24 (42.11) controls vs FTD
patients: p = 0.460
36 (31.58) 78 (68.42) controls vs FTD
patients: p = 0.806
Differences between 4 
groups: p = 0.821
Differences between 4 
groups: p = 0.823
rs2233682 GG GA AA p-value G A p-valueBMC Medical Genetics 2009, 10:115 http://www.biomedcentral.com/1471-2350/10/115
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type association with AD in the Northern Italian popula-
tion, however, they were consistent with the data from the
American, French and other Italian cohorts [26-28]. The
identified variants g.9805834T>C, c.24C>T and
c.382+105C>T are all located on the most prevalent hap-
lotypes, CGTGCA/GGCGCG. The patients with variant
c.58+64C>T belonged to diplotypes CGTGCA/CGCGCA,
CCCGCG/CGCACA and CCCGTA/CGCACA.
We did not identify sequence variants or haplotype asso-
ciated with the risk for FTD. On one hand enrolling FTD
patients without neuropathological characterization
could be seen as a weakness of our study, not allowing us
to stratify this group according to tau pathology. How-
ever, Thorpe et al (2004) identified PIN1 depletion in FTD
with and without tau pathology [7].
Controls 103 (99.04) 1 (0.96) 0 (0.00) controls vs LOAD
patients: p = 1.00
207 (99.52) 1 (0.48) controls vs LOAD
patients: p = 1.00
LOAD patients 110 (99.10) 1 (0.90) 0 (0.00) 221 (99.55) 1 (0.45)
EOAD patients 48 (97.96) 1 (2.04) 0 (0.00) controls vs EOAD
patients: p = 1.00
97 (98.98) 1 (1.02) controls vs EOAD
patients: p = 1.00
FTD patients 57 (100.00) 0 (0.00) 0 (0.00) controls vs FTD
patients: p = 1.00
114 (100.00) 0 (0.00) controls vs FTD
patients: p = 1.00
Differences between 4 
groups: p = 0.654
Differences between 4 
groups: p = 0.655
rs2233683 CC CT TT p-value C T p-value
Controls 100 (96.15) 4 (3.85) 0 (0.00) controls vs LOAD
patients: p = 0.540
204 (98.1) 4 (1.9) controls vs LOAD
patients: p = 0.617
LOAD patients 104 (93.69) 7 (6.31) 0 (0.00) 215 (96.85) 7 (3.15)
EOAD patients 49 (100.00) 0 (0.00) 0 (0.00) controls vs EOAD
patients: p = 0.306
98 (100.00) 0 (0.00) controls vs EOAD
patients: p = 0.310
FTD patients 57 (100.00) 0 (0.00) 0 (0.00) controls vs FTD
patients: p = 0.298
114 (100.00) 0 (0.00) controls vs FTD
patients: p = 0.301
Differences between 4 
groups: p = 0.089
Differences between 4 
groups: p = 0.095
rs2010457 AA AG GG p-value A G p-value
Controls 52 (50.00) 45 (43.27) 7 (6.73) controls vs LOAD
patients: p = 0.923
149 (71.6) 59 (28.4) controls vs LOAD
patients: p = 0.752
LOAD patients 54 (48.65) 48 (43.24) 9 (8.11) 156 (70.3) 66 (29.7)
EOAD patients 20 (40.82) 25 (51.02) 4 (8.16) controls vs EOAD
patients: p = 0.484
65 (66.3) 33 (33.7) controls vs EOAD
patients: p = 0.322
FTD patients 24 (42.11) 28 (49.12) 5 (8.77) controls vs FTD
patients: p = 0.504
76 (66.7) 38 (33.3) controls vs FTD
patients: p = 0.264
Differences between 4 
groups: p = 0.926
Differences between 4 
groups: p = 0.703
Table 1: Frequencies of six heterozygous in the Polish population PIN1 polymorphisms (Continued)BMC Medical Genetics 2009, 10:115 http://www.biomedcentral.com/1471-2350/10/115
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Additionally, we identified four novel PIN1 sequence var-
iants in six patients with familial AD (Table 3). One vari-
ant was found in the PIN1  promoter region
(g.9805834T>C), one in exon 1 (a silent substitution
c.24C>T) and two in introns 1 and 3 (c.58+64C>T and
c.382+105C>T). None of them was found in the previous
studies [26,28]. Variant c.382+105C>T due to its location
is rather unlikely to affect splicing of PIN1. The putative
role of other variants is described below. All of them could
potentially influence PIN1 expression and/or splicing.
In silico analysis of g.9805834T>C variant
In silico analysis of the identified g.9805834T>C promoter
variant using Matinspector predicted that it could disrupt
the binding sites for four transcription factors/transcrip-
tion factor families: FAST-1 SMAD interacting proteins,
PAR/bZIP family, CCAAT/Enhancer Binding Protein (C/
EBPs) and Ikaros zinc finger family. Similar analysis per-
formed by another tool, Mapper, confirmed loss of the
sites for C/EBPs and PAR/bZIP family, which could be due
to similarities between the consensus sequences recog-
nized by both leucine zipper transcription factor families.
In both analyses C/EBP binding site obtained higher
matrix similarity scores than the PAR/bZIP family.
The CCAAT/Enhancer Binding Proteins (C/EBPs) belong
to the superfamily of transcription factors, which includes
c-Jun, c-Fos and cAMP response element binding protein
(CREB). C/EBPβ is required for neuronal differentiation,
maturation and apoptosis [43-45]. Additionally, it plays
Table 2: Frequency of PIN1 haplotypes in LOAD, EOAD and FTD patients compared with the control group
Haplotype * Controls 
(%)
All patients 
(LOAD, 
EOAD and 
FTD) 
together (%)
p value for 
all patients 
together vs 
controls
LOAD (%) p value for 
LOAD vs 
controls
EOAD (%) p value for 
EOAD vs 
controls
FTD (%) p value for 
FTD vs 
controls
CGTGCA 68.7 66.1 0.510 67.1 0.717 64.3 0.438 65.8 0.588
GGCGCG 17.8 18.4 0.844 17.6 0.951 18.4 0.902 20.2 0.599
CCCGCG 8.7 11.3 0.307 9.9 0.654 15.3 0.080 10.5 0.581
CGTGCG 1.0 1.2 0.835 0.9 0.948 0.0 0.333 2.7 0.253
CCCGTA 1.0 1.2 0.838 2.3 0.294 0.0 0.329 0.0 0.291
GGCGCA 1.0 0.5 0.458 0.0 0.149 1.0 0.962 0.9 0.942
CCCGTG 0.9 0.5 0.459 0.9 0.954 0.0 0.331 0.0 0.296
CGCACA 0.5 0.5 0.972 0.5 0.963 1.0 0.585 0.0 0.458
CCCGCA 0.5 0.0 0.151 0.0 0.303 0.0 0.495 0.0 0.463
CGCGCA 0.0 0.2 0.488 0.5 0.332 0.0 - 0.0 -
GCCGCG 0.0 0.2 0.488 0.5 0.332 0.0 - 0.0 -
* The five haplotype loci correspond to SNPs 1-6 in Figure 1
Table 3: New sequence variants in PIN1 and brief description of their carriers.
Variant Diagnosis Gender Age at onset (years) family history of 
dementia (+/-)
APOE genotype Tumors
g.9805834T>C LOAD male 70 + (mother had memory and 
behavioral disturbances at 
the age of 60)
34 benign prostate 
hyperplasia
c.24G>T EOAD female 52 + 
(mother and father's 
mother)
33 no data
c.58+64C>T EOAD female 51 + (father) 44 goiter, benign thyroid 
tumor
LOAD female 71 + 
(mothers's brother suffered 
from dementia)
34 osteoma ossis frontalis
LOAD female 70 + (father in his eighties 
developed AD symptoms, 
sister at the age of 66 had 
psychiatric problems)
34 nodular goitre, breast 
cancer
c.382+105C>T EOAD male 48 + 
(father had dementia and 
died at the age of 73)
34 noneBMC Medical Genetics 2009, 10:115 http://www.biomedcentral.com/1471-2350/10/115
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an important role in the consolidation of mammalian
long-term memory and in synaptic plasticity [46,47].
The activity of C/EBPs depends on the phosphorylation
status of their Ser/Thr-Pro motifs and PIN1 was suggested
to participate in their post-translational modifications
[48]. Mutual interactions of both proteins can affect their
common partner, E2F. It was demonstrated that PIN1
expression is mediated by E2F [49] and that C/EBPβ regu-
lates E2F target gene activation by interacting with E2F
and presumably by binding to their promoters [16]. Anal-
ysis of the whole PIN1  promoter region revealed one
(Mapper) or two (Matinspector) binding sites for C/EBPs
in the promoter sequence. Therefore, the loss of C/EBP
binding site by g.9805834T>C variant might affect EF2
mediated activation of PIN1 transcription.
In silico analysis of c.24G>T variant
c.24G>T is a synonymous substitution (8Pro, CCG>CCT),
localized in a region participating in the PIN1 WW
domain formation, responsible for binding hyperphos-
phorylated Tau [5]. ConSeq predicted that 8Pro is a highly
conserved residue. In addition, Multiple Sequence Align-
ment revealed that this position is highly conserved
between human PIN1 and its homologs in several species
(e.g. Pan troglodytes, Canis lupus familiaris, Bos taurus, Dro-
sophila melanogaster). Moreover, the proline is also con-
served between human PIN1 and its yeast ortholog,
Ess1p.
Despite c.24G>T variant does not affect protein coding, it
might disrupt specific splicing elements. Recently, it has
been acknowledged that silent changes have the potential
to alter the efficiency and specificity of splicing, and con-
tribute to phenotypic variability [50,51].
Analysis of exon 1 sequence by software that detects
exonic splicing enhancer (ESE) sites indicated that
c.24G>T variant is located within five putative ESE (Table
4). Importantly, using the default settings of ESEfinder,
the program predicted that this transversion might disrupt
one putative ESE recognized by SF2/ASF, reduce high
score of another SF2/ASF motif and enhance binding of
SF2/ASF (IgM-BRCA1). ESEfinder anticipated that
c.24G>T mutation might shift a putative responsive site
for SC35 four nucleotides downstream PIN1 sequence.
Moreover, c.24G>T could increase binding of SRp55 and
generate SRp40 motif. However, the new putative SRp40
motif (CCTCCCG) would overlap with the recognition
site for SF2/ASF (IgM-BRCA1) (CTCCCGG). Simultane-
ous binding of two overlapping ESEs is considered as
rather unlikely [51].
Analysis of c.58+64C>T variant
Variant c.58+64C>T (according to the GenBank accession
numbers NM_006221 and NC_000019.8) was identified
in three female patients, one with familial EOAD
(fEOAD) and two with familial LOAD (fLOAD). The ear-
lier age at onset of the patient with EOAD (54 years) could
be explained by carrying two alleles of APOE4 in compar-
ison with two LOAD patients (aged 70 and 71 years) with
the same variant but genotype APOE3/4. As dose-effect
relation data on APOE4 allele suggests, homozygosity for
APOE4 might have accelerated the age at onset in carrier
of c.58+64C>T variant [52].
Importantly, c.58+64C>T substitution is located in an
alternative exon found selectively in testis (The AceView
genes: http://www.ncbi.nlm.nih.gov/IEB/Research/Acem
bly). An online tool, Automated Splice Site Analysis,
revealed that c.58+64C>T substitution increases 14.3 fold
the strength of a potential binding site for SC35 situated
one nucleotide upstream the variant. Previously, SC35
was reported to be responsible for aberrant splicing of the
E1α Puryvate Dehydrogenase (PDHA1) mRNA in mental
retardation with lactic acidosis [53,54]. Moreover,
RegRNA program revealed that the c.58+64C>T substitu-
tion introduces two intronic splicing enhancers, an
intronic AGGG motif (on + strand) and CTGC (on -
strand). (A/U)GGG motif was shown to enhance alterna-
tive splicing of the chicken beta-tropomyosin pre-mRNA
[55], thus introduction of another (A/U)GGG motif to the
three preexisting ones in the 5' part of intron 1 could affect
its splicing.
Variant c.58+64C>T in the patient with AAO of 51 years
was associated with a 2.82 fold decreased PIN1 expression
in the blood leukocytes. As decreased PIN1 level was pre-
viously observed in brains of Alzheimer's disease patients
[2,7,15], it raises the possibility that identified variant
could exert more profound effects in the brain.
Presented results concerning c.58+64C>T variant are con-
sistent with the hypothesis linking PIN1 downregulation
with amyloidogenic APP processing and aberrant cell
cycle re-entry. As it stemmed from the observations of
Table 4: Effect of c.24G>T mutation on calculated exonic splicing 
enhancer motifs scores.
SR protein c.24G c.24T
SF2/ASF (1) Score = 2.02 0
SF2/ASF (2) Score = 4.42 ↓ Score = 3.75
SF2/ASF (IgM-BRCA1) Score = 2.758 ↑ Score = 4.13
SC35 (1) Score = 2.93 0
SC35 (2) 0 ↑ Score = 3.54
SRp40 0 Score = 2.88
SRp55 Score = 3.02 ↑ Score = 3.83
Only motifs distinguishing wild type DNA sequence and the one with 
mutation c.24G>T, with scores above the thresholds, are presented.BMC Medical Genetics 2009, 10:115 http://www.biomedcentral.com/1471-2350/10/115
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Fanghänel and coworkers (2006), even a basal level of
PPIase activity complement a lethal cell cycle dysfunction
related to PIN1 dysfunction at the single cell level [56].
However, in organs with high levels of PIN1 activity, like
brain and testis, the basal activity is not sufficient to com-
plement the pathology. This observation suggests that
decrease in PIN1 activity in human brain could lead to
neurodegeneration. The deleterious effect could be medi-
ated either by oxidative stress, or by rare PIN1 sequence
variation.
Conclusion
Despite our data do not directly support the role of com-
mon PIN1 polymorphisms as AD risk factor, presented
results concerning c.58+64C>T variant could be inter-
preted as being consistent with the hypothesis linking
PIN1 downregulation with amyloidogenic APP process-
ing and aberrant cell cycle re-entry. Presented data of the
identification of four new PIN1 sequence variants under-
score the importance of further studies on PIN1 variation
in familial AD patients. None of the variants was con-
nected with very early onset AD and/or rapid progression
of the disease. Therefore, our findings suggest that PIN1
variants could be causally connected with familial AD
with age at onset ranging from 45 to 75 years.
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